Last reviewed · How we verify
Systemic and Intra-Thecal Amikacin Therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Systemic and Intra-Thecal Amikacin Therapy (Systemic and Intra-Thecal Amikacin Therapy) — Rambam Health Care Campus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Systemic and Intra-Thecal Amikacin Therapy TARGET | Systemic and Intra-Thecal Amikacin Therapy | Rambam Health Care Campus | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Systemic and Intra-Thecal Amikacin Therapy CI watch — RSS
- Systemic and Intra-Thecal Amikacin Therapy CI watch — Atom
- Systemic and Intra-Thecal Amikacin Therapy CI watch — JSON
- Systemic and Intra-Thecal Amikacin Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Systemic and Intra-Thecal Amikacin Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/systemic-and-intra-thecal-amikacin-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab